Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial

VS Chachay, Jennifer H Martin, JB Prins, JP Whitehead, Trisha M O'Moore-Sullivan, Paul Lee, M Franklin, K Klein, PJ Taylor, Maree Ferguson, JS Coombes, Gethin Thomas, Gary J Cowin, C. Kirkpatrick, graeme MacDonald, Ingrid Hickman

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.
    Original languageEnglish
    Pages (from-to)78-79
    Number of pages2
    JournalJournal of Gastroenterology and Hepatology (Australia)
    Volume28
    Issue numberSupplement 2
    Publication statusPublished - 2013

    Fingerprint

    Dyslipidemias
    Insulin Resistance
    Placebos
    Pharmacology
    Liver
    Vitis
    Wine
    Dietary Supplements
    Metabolic Networks and Pathways
    Liver Diseases
    Hepatocytes
    Fruit
    Triglycerides
    Oxidative Stress
    Chronic Disease
    Animal Models
    Obesity
    Inflammation
    Safety
    Food

    Cite this

    Chachay, VS., Martin, J. H., Prins, JB., Whitehead, JP., O'Moore-Sullivan, T. M., Lee, P., ... Hickman, I. (2013). Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial. Journal of Gastroenterology and Hepatology (Australia), 28(Supplement 2), 78-79.
    Chachay, VS ; Martin, Jennifer H ; Prins, JB ; Whitehead, JP ; O'Moore-Sullivan, Trisha M ; Lee, Paul ; Franklin, M ; Klein, K ; Taylor, PJ ; Ferguson, Maree ; Coombes, JS ; Thomas, Gethin ; Cowin, Gary J ; Kirkpatrick, C. ; MacDonald, graeme ; Hickman, Ingrid. / Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease : A randomised, double blind, placebo-controlled trial. In: Journal of Gastroenterology and Hepatology (Australia). 2013 ; Vol. 28, No. Supplement 2. pp. 78-79.
    @article{d38f17fc36454462b3a1a44dbca1a4fc,
    title = "Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial",
    abstract = "Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.",
    author = "VS Chachay and Martin, {Jennifer H} and JB Prins and JP Whitehead and O'Moore-Sullivan, {Trisha M} and Paul Lee and M Franklin and K Klein and PJ Taylor and Maree Ferguson and JS Coombes and Gethin Thomas and Cowin, {Gary J} and C. Kirkpatrick and graeme MacDonald and Ingrid Hickman",
    year = "2013",
    language = "English",
    volume = "28",
    pages = "78--79",
    journal = "Journal of Gastroenterology and Hepatology (Australia)",
    issn = "0815-9319",
    publisher = "Wiley-Blackwell",
    number = "Supplement 2",

    }

    Chachay, VS, Martin, JH, Prins, JB, Whitehead, JP, O'Moore-Sullivan, TM, Lee, P, Franklin, M, Klein, K, Taylor, PJ, Ferguson, M, Coombes, JS, Thomas, G, Cowin, GJ, Kirkpatrick, C, MacDonald, G & Hickman, I 2013, 'Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial', Journal of Gastroenterology and Hepatology (Australia), vol. 28, no. Supplement 2, pp. 78-79.

    Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease : A randomised, double blind, placebo-controlled trial. / Chachay, VS; Martin, Jennifer H; Prins, JB; Whitehead, JP; O'Moore-Sullivan, Trisha M; Lee, Paul; Franklin, M; Klein, K; Taylor, PJ; Ferguson, Maree; Coombes, JS; Thomas, Gethin; Cowin, Gary J; Kirkpatrick, C.; MacDonald, graeme ; Hickman, Ingrid.

    In: Journal of Gastroenterology and Hepatology (Australia), Vol. 28, No. Supplement 2, 2013, p. 78-79.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease

    T2 - A randomised, double blind, placebo-controlled trial

    AU - Chachay, VS

    AU - Martin, Jennifer H

    AU - Prins, JB

    AU - Whitehead, JP

    AU - O'Moore-Sullivan, Trisha M

    AU - Lee, Paul

    AU - Franklin, M

    AU - Klein, K

    AU - Taylor, PJ

    AU - Ferguson, Maree

    AU - Coombes, JS

    AU - Thomas, Gethin

    AU - Cowin, Gary J

    AU - Kirkpatrick, C.

    AU - MacDonald, graeme

    AU - Hickman, Ingrid

    PY - 2013

    Y1 - 2013

    N2 - Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.

    AB - Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.

    M3 - Article

    VL - 28

    SP - 78

    EP - 79

    JO - Journal of Gastroenterology and Hepatology (Australia)

    JF - Journal of Gastroenterology and Hepatology (Australia)

    SN - 0815-9319

    IS - Supplement 2

    ER -